Sernova

Philip Toleikis, Ph.D., President and CEO

April 20 | 11:30am | Gaudi 3 Ballroom

Ontario, Canada

(TSX: SVA)

In-Person Presentation

Sernova is a clinical-stage regenerative medicine company developing therapeutic solutions with multibillion-dollar market potential for each of its clinical indications. Sernova’s Cell Pouch System, comprised of a small implantable vascularized device forming an organ-like environment for the transplantation of immune protected therapeutic cells creates an effective, safe, long-term, and convenient therapeutic option for patients with chronic disease who seek to improve their quality of life. Sernova is currently conducting a U.S. Phase I/II clinical trial at the University of Chicago in type 1 diabetic patients with severe hypoglycemia unawareness. Interim assessment results have demonstrated clinical benefit and our first treated subject has been insulin free for over 20 months, providing a functional cure. Sernova is also embarking on a second clinical application for patients with thyroid disease and has completed ex vivo gene therapy preclinical proof of concept for hemophilia A, an orphan status application.

www.sernova.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions